The direct costs of multiple sclerosis-study in the Czech Republic
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62690094%3A18450%2F18%3A50014697" target="_blank" >RIV/62690094:18450/18:50014697 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11150/18:10384939 RIV/00179906:_____/18:10384939
Result on the web
<a href="https://link.springer.com/article/10.1007/s10072-018-3551-7" target="_blank" >https://link.springer.com/article/10.1007/s10072-018-3551-7</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s10072-018-3551-7" target="_blank" >10.1007/s10072-018-3551-7</a>
Alternative languages
Result language
angličtina
Original language name
The direct costs of multiple sclerosis-study in the Czech Republic
Original language description
Background: Multiple sclerosis (MS) is a progressive autoimmune disease of the central nervous system that is often disabling and for which there is currently no cure, though disease-modifying treatment is now available. The aim of this study is to describe the current values of the direct costs of multiple sclerosis (MS) in the Czech Republic. Methods: Attention is focused on direct medical costs. The costs were monitored in the Czech Republic among 5673 patients in the period between 2011 and 2015. These costs included complex, special and targeted visits at the neurologist, blood collection and the costs of hospitalisation. The results refer to the diagnoses according to the International Statistical Classification of Diseases and Related Health Problems. The attention is focused on MS G35 (NS; brain stem; spinal cord; disseminated; generalised). Results: The average total direct costs per patient per year are 4838.1 €. Not every patient has to be hospitalised during the year, and not every patient has prescribed medication. According to the above data, 12% of patients are hospitalised and 55% of patients are prescribed medication. The minimum average cost per patient without medication and hospitalisation is 54.1 €. Conclusion: Cost evaluation across countries is difficult due to the different evidence. If only selected direct costs considered in this study are compared, the absolute economics burden increases over time. The only statistically significant difference in the average price and the time spent is between 2012 and 2013, where the correlation value is 0.597.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
50202 - Applied Economics, Econometrics
Result continuities
Project
<a href="/en/project/TL01000300" target="_blank" >TL01000300: Treatment and care of people with Alzheimer's disease - economic burden in the context of the development of new drugs</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Neurological sciences
ISSN
1590-1874
e-ISSN
—
Volume of the periodical
39
Issue of the periodical within the volume
12
Country of publishing house
IT - ITALY
Number of pages
7
Pages from-to
2115-2121
UT code for WoS article
000452518300012
EID of the result in the Scopus database
2-s2.0-85053373870